Diana Merino Vega

10PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersLiquid biopsiesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment.

Aleksandra Markovets, Diana Merino Vega, Chris Abbosh

|Sep 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy.

Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura

|Apr 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura

|Mar 12, 2025
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium.

Andrew G Hadd, Angela Silvestro, Brittany Avin McKelvey

|Aug 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Diana Merino Vega, Katherine K Nishimura, Névine Zariffa

|Feb 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.

Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje

Pageof 2

Frequent Collaborators

5 joint publications

Mark Stewart

2 joint publications

Névine Zariffa

2 joint publications

Brittany Avin McKelvey

2 joint publications

Katherine K Nishimura